Brief: Interpace Biosciences Q3 Revenue $8.2 Million Versus Refinitiv Ibes Estimate Of $7.6 Million

Interpace Biosciences

20/01/2021 13:51

Jan 20 (Reuters) - Interpace Biosciences Inc  IDXG.O :
    * Q3 REVENUE $8.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF
$7.6
MILLION
    * SEES Q4 REVENUE $9.0 MILLION TO $10 MILLION
    * CASH BALANCE AS OF JANUARY 15, 2021 WAS $6.1 MILLION NET
OF
RESTRICTED CASH
    * INTERPACE BIOSCIENCES - QTRLY LOSS PER SHARE $1.54

Source text for Eikon:  ID:nGNX1fJVLm 
Further company coverage:  IDXG.O 

 ((Reuters.Briefs@thomsonreuters.com;))